C1420T Polymorphism of Cytosolic Serine Hydroxymethyltransferase and Risk of Cancer: a Meta-analysis

  • Zhong, Shan-Liang (Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University) ;
  • Zhang, Jun (College of traditional Chinese medicine, Anhui University of Chinese Medicine) ;
  • Hu, Qing (Teaching and Research Office of General Surgery, Xuzhou Medical College) ;
  • Chen, Wei-Xian (The Fourth Clinical College of Nanjing Medical University) ;
  • Ma, Teng-Fei (Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University) ;
  • Zhao, Jian-Hua (Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University)
  • Published : 2014.03.01


A series of studies have explored the role of cytosolic serine hydroxymethyltransferase (SHMT1) C1420T polymorphism in cancer risk, but their results were conflicting rather than conclusive. To derive a more precise estimation of the association between C1420T and cancer risk, the present meta-analysis of 28 available studies with 15,121 cases and 18,023 controls was conducted. The results revealed that there was no significant association between the polymorphism and cancer risk overall. In stratified analysis by cancer type (breast cancer, gastrointestinal cancer, leukemia, lymphoma, and others), the results showed that 1420T allele was associated with decreased risk in leukemia (CT vs. CC: OR= 0.825, 95% CI =0.704-0.966; and CT+TT vs. CC: OR= 0.838, 95% CI = 0.722-0.973), but the same results were not present for other cancer types. When subgroup analysis was performed by source of control (population-based [PB] and hospital-based [HB]), a borderline inverse association was observed for the HB subgroup (CT vs. CC: OR= 0.917, 95% CI = 0.857-0.982) but not for the PB subgroup. Stratifying by geographic area (America, Asia and Europe), significant inverse association was only found in Asia subgroup (CT vs. CC: OR= 0.674, 95% CI = 0.522-0.870). In summary, the findings suggest that SHMT1 C1420T polymorphism is not associated with overall cancer development, but might decrease cancer susceptibility of Asians as well as reduce leukemia risk. Large well-designed epidemiological studies will be necessary to validate the risk identified in the current meta-analysis.


  1. Berglund M, Enblad G, Turesson I, Edman V, Thunberg U (2009). Folate-metabolizing genes in lymphoma patients from Sweden. Scand J Immunol, 70, 408-10.
  2. Blount BC, Mack MM, Wehr CM, et al (1997). Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA, 94, 3290-5.
  3. Carvalho Barbosa Rde C, Menezes DC, Freire TF, et al (2012). Associations of polymorphisms of folate cycle enzymes and risk of breast cancer in a Brazilian population are age dependent. Mol Biol Rep, 39, 4899-907.
  4. Chen J, Kyte C, Valcin M, et al (2004). Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer, 110, 617-20.
  5. Cheng CW, Yu JC, Huang CS, et al (2008). Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan. Breast Cancer Res Treat, 111, 145-55.
  6. Curtin K, Ulrich CM, Samowitz WS, et al (2011). Candidate pathway polymorphisms in one-carbon metabolism and risk of rectal tumor mutations. Int J Mol Epidemiol Genet, 2, 1-8.
  7. Das PM, Singal R (2004). DNA methylation and cancer. J Clin Oncol, 22, 4632-42.
  8. de Jonge R, Tissing WJ, Hooijberg JH, et al (2009). Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood, 113, 2284-9.
  9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  10. Duthie SJ, Narayanan S, Brand GM, Pirie L, Grant G (2002). Impact of folate deficiency on DNA stability. J Nutr, 132, 2444S-9S.
  11. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  12. Galbiatti AL, da Silva LM, Ruiz-Cintra MT, et al (2012). Association between 11 genetic polymorphisms in folatemetabolising genes and head and neck cancer risk. Eur J Cancer, 48, 1525-31.
  13. Gibson TM, Brennan P, Han S, et al (2011). Comprehensive Evaluation of One-Carbon Metabolism Pathway Gene Variants and Renal Cell Cancer Risk. PLoS One, 6.
  14. Girgis S, Suh JR, Jolivet J, Stover PJ (1997). 5-Formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma. J Biol Chem, 272, 4729-34.
  15. Guerreiro CS, Carmona B, Goncalves S, et al (2008). Risk of colorectal cancer associated with the C677T polymorphism in 5, 10-methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients. Am J Clin Nutr, 88, 1413-8.
  16. Hazra A, Wu K, Kraft P, et al (2007). Twenty-four nonsynonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study. Carcinogenesis, 28, 1510-9.
  17. Heil SG, Van der Put NM, Waas ET, et al (2001). Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab, 73, 164-72.
  18. Hishida A, Matsuo K, Hamajima N, et al (2003). Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica, 88, 159-66.
  19. Jiang Y, Hou J, Zhang Q, et al (2013). The MTHFR C677T polymorphism and risk of acute lymphoblastic leukemia: an updated meta-analysis based on 37 case-control studies. Asian Pac J Cancer Prev, 14, 6357-62.
  20. Kasperzyk JL, Chang ET, Birmann BM, et al (2011). Nutrients and genetic variation involved in one-carbon metabolism and Hodgkin lymphoma risk: a population-based case-control study. Am J Epidemiol, 174, 816-27.
  21. Kim YI (1999). Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem, 10, 66-88.
  22. Komlosi V, Hitre E, Pap E, et al (2010). SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer. BMC Cancer, 10, 525.
  23. Koushik A, Kraft P, Fuchs CS, et al (2006). Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev, 15, 2408-17.
  24. Lautner-Csorba O, Gezsi A, Erdelyi DJ, et al (2013). Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by bayesian relevance and effect size analysis. PLoS One, 8, e69843.
  25. Lee KM, Lan Q, Kricker A, et al (2007). One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet, 122, 525-33.
  26. Li Q, Lan Q, Zhang Y, et al (2013). Role of one-carbon metabolizing pathway genes and gene-nutrient interaction in the risk of non-Hodgkin lymphoma. Cancer Causes Control, 24, 1875-84.
  27. Lichtenstein P, Holm NV, Verkasalo PK, et al (2000). Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85.
  28. Lightfoot TJ, Johnston WT, Painter D, et al (2010). Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood, 115, 3923-9.
  29. Lightfoot TJ, Skibola CF, Willett EV, et al (2005). Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomarkers Prev, 14, 2999-3003.
  30. Lim U, Wang SS, Hartge P, et al (2007). Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCISEER case-control study. Blood, 109, 3050-9.
  31. Lissowska J, Gaudet MM, Brinton LA, et al (2007). Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a population-based case-control study and meta-analyses. Int J Cancer, 120, 2696-703.
  32. Liu AY, Scherer D, Poole E, et al (2013). Gene-diet-interactions in folate-mediated one-carbon metabolism modify colon cancer risk. Mol Nutr Food Res, 57, 721-34.
  33. Lucock M (2004). Is folic acid the ultimate functional food component for disease prevention? BMJ, 328, 211-4.
  34. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  35. Metayer C, Scelo G, Chokkalingam AP, et al (2011). Genetic variants in the folate pathway and risk of childhood acute lymphoblastic leukemia. Cancer Cause Control, 22, 1243-58.
  36. Mohammad NS, Yedluri R, Addepalli P, et al (2011). Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. Mol Cell Biochem, 349, 159-67.
  37. Moore LE, Malats N, Rothman N, et al (2007). Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer, 120, 2452-8.
  38. Morita M, Yin G, Yoshimitsu S, et al (2013). Folate-related nutrients, genetic polymorphisms, and colorectal cancer risk: the fukuoka colorectal cancer study. Asian Pac J Cancer Prev, 14, 6249-56.
  39. Naushad SM, Pavani A, Digumarti RR, Gottumukkala SR, Kutala VK (2011a). Epistatic interactions between loci of one-carbon metabolism modulate susceptibility to breast cancer. Mol Biol Rep, 38, 4893-901.
  40. Naushad SM, Pavani A, Rupasree Y, et al (2012). Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer. Mol Carcinog, 51 Suppl 1, E32-41.
  41. Naushad SM, Pavani A, Rupasree Y, et al (2011b). Modulatory effect of plasma folate and polymorphisms in one-carbon metabolism on catecholamine methyltransferase (COMT) H108L associated oxidative DNA damage and breast cancer risk. Indian J Biochem Biophys, 48, 283-9.
  42. Niclot S, Pruvot Q, Besson C, et al (2006). Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. Blood, 108, 278-85.
  43. Patino-Garcia A, Zalacain M, Marrodan L, San-Julian M, Sierrasesumaga L (2009). Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr, 154, 688-93.
  44. Piskac-Collier AL, Monroy C, Lopez MS, et al (2011). Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer, 50, 1-12.
  45. Sharp S (1998). sbe23: Meta-analysis regression. Stata Technical Bulletin, 42, 16-22.
  46. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
  47. Skibola CF, Forrest MS, Coppede F, et al (2004). Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood, 104, 2155-62.
  48. Skibola CF, Smith MT, Hubbard A, et al (2002). Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood, 99, 3786-91.
  49. Steck SE, Keku T, Butler LM, et al (2008). Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk. J Nutrigenet Nutrigenomics, 1, 196-204.
  50. Swartz MD, Peterson CB, Lupo PJ, et al (2013). Investigating Multiple Candidate Genes and Nutrients in the Folate Metabolism Pathway to Detect Genetic and Nutritional Risk Factors for Lung Cancer. PLoS One, 8.
  51. Tan X, Wang YY, Dai L, Liao XQ, Chen MW (2013). Genetic polymorphism of MTHFR A1298C and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 14, 1951-5.
  52. Vainer AS, Boiarskikh UA, Voronina EN, et al (2010). [Polymorphic variants of folate metabolizing genes (C677T and A1298C MTHFR, C1420T SHMT1 and G1958A MTHFD) are not associated with the risk of breast cancer in West Siberian Region of Russia]. Mol Biol, 44, 816-23.
  53. van den Donk M, Visker MH, Harryvan JL, Kok FJ, Kampman E (2007). Dietary intake of B-vitamins, polymorphisms in thymidylate synthase and serine hydroxymethyltransferase 1, and colorectal adenoma risk: a Dutch case-control study. Cancer Lett, 250, 146-53.
  54. Wang L, Lu J, An J, et al (2007a). Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: a case-control analysis. Lung Cancer, 57, 143-51.
  55. Wang Y, Guo W, He Y, et al (2007b). Association of MTHFR C677T and SHMT (1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Cause Control, 18, 143-52.
  56. Wang YM, Guo W, Zhang XF, et al (2006). Correlations between serine hydroxymethyltransferase1 C1420T polymorphisms and susceptibilities to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng, 25, 281-6 (in Chinese).
  57. Weiner AS, Beresina OV, Voronina EN, et al (2011). Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin's lymphoma. Leuk Res, 35, 508-15.
  58. Weiner AS, Boyarskih UA, Voronina EN, et al (2010). Polymorphic variants of folate metabolizing genes (C677T and A1298C MTHFR and C1420T SHMT1 and G1958A MTHFD) are not associated with the risk of breast cancer in the West Siberian Region of Russia. Molecular Biology, 44, 720-7.
  59. Weiner AS, Oskina NA, Lacarev AF, et al (2012). Role of polymorphic variants of MTR gene A2756G and SHMT1 gene C1420T in the development of prostatic cancer in residents of the Western Siberian Region of Russia. Bull Exp Biol Med, 152, 466-9.
  60. Yang L, Liu L, Wang J, et al (2011). Polymorphisms in folaterelated genes: impact on risk of adult acute lymphoblastic leukemia rather than pediatric in Han Chinese. Leuk Lymphoma, 52, 1770-6.
  61. Yu CP, Wu MH, Chou YC, et al (2007). Breast cancer risk associated with multigenotypic polymorphisms in folatemetabolizing genes: a nested case-control study in Taiwan. Anticancer Res, 27, 1727-32.
  62. Zhang Z, Shi Q, Sturgis EM, Spitz MR, Wei Q (2005). Polymorphisms and haplotypes of serine hydroxymethyltransferase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Pharmacogenet Genomics, 15, 557-64.

Cited by

  1. Insulin resistance and glycine metabolism in humans pp.1438-2199, 2017,